Evidence map›Paper›PMID 32055642›Full record

ArticleOpen forum infectious diseases2020

Soluble T-Cell Immunoglobulin Mucin Domain-3 Is Associated With Hepatitis C Virus Coinfection and Low-Grade Inflammation During Chronic Human Immunodeficiency Virus Infection.

Hedda Hoel, Thor Ueland, Malene Hove-Skovsgaard, Hans Jakob Hartling, Marco Gelpi, Thomas Benfield, Henrik Ullum, Annika E Michelsen, Pål Aukrust, Susanne Dam Nielsen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Elevated plasma sTIM-3 levels in patients with severe COVID-19.The Journal of allergy and clinical immunology · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Hedda HoelResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Thor UelandResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Malene Hove-SkovsgaardDepartment of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Hans Jakob HartlingDepartment of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Marco GelpiDepartment of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Thomas BenfieldDepartment of Infectious Diseases, Amager Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
Henrik UllumDepartment of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Annika E MichelsenResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Susanne Dam NielsenDepartment of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Marius TrøseidResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Oslo University Hospital · NOCopenhagen University Hospital · DKRigshospitalet · DKHvidovre Hospital · DKLovisenberg Diakonale Høgskole · NOUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn well treated human immunodeficiency virus infection (HIV), there is a residual immune activation and immune exhaustion that may contribute to increased risk of comorbidities. T-cell immunoglobulin mucin domain-3 (Tim-3) is an inhibitory molecule involved in HIV-associated T-cell dysfunction. The Tim-3 can be cleaved to soluble Tim-3 (sTim-3) that may serve as a soluble marker of immune exhaustion.

methodsWe measured sTim-3 with enzyme-linked immunosorbent assay DuoSets in a cross-sectional cohort of 1010 people with HIV (PWH) on antiretroviral therapy (ART), and 76 controls from the Copenhagen Co-Morbidity in HIV Infection (COCOMO) study, and in a longitudinal cohort of 60 PWH before and during ART.

resultsIn the cross-sectional cohort, levels of sTim-3 were elevated in PWH on ART compared with controls, especially in hepatitis C virus (HCV)-coinfected individuals, and were associated with HCV viremia and inflammation. In the longitudinal cohort, pretreatment sTim-3 correlated with HIV viral load and decreased after ART initiation. Pretreatment sTim-3 correlated inversely with CD4 counts, but it did not predict immunological response in multivariable analyses.

conclusionsLevels of sTim-3 decreased after ART initiation. In a cross-sectional cohort, levels of sTIM-3 were higher in PWH than in controls and were independently associated with HCV coinfection and high-sensitivity C-reactive protein, representing a potential link between immune exhaustion, inflammation, and risk of comorbidities.

Indexed as

hepatitis CHIVimmune exhaustionsolubleTim-3

Identifiers

PMID32055642
PMCPMC7009472
OpenAlexW3003907695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.